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Prions prefer caveosomes
 
he story of prions gets increasingly 
bizarre. The peculiar pathogenicity of 
prion protein (PrP) makes understanding 
and treating the resulting diseases difficult. 
Now, on page 703, Peters et al. provide 
evidence that PrP also uses an unusual 
endocytic pathway en route to lysosomes.
The harmless version of PrP is processed 
and directed to caveolin-rich glycolipid 
rafts at the plasma membrane, although its 
function remains a mystery. The mis-
folded pathogenic form, however, is found 
T
PrP (small gold particles) is found in endocytic structures with caveolin-1 (large particles).
 
in late endosomes and lysosomes. The group now shows that, 
unlike most internalized proteins, which use the typical clathrin-
dependent endocytosis pathway, PrP finds its way to lysosomes 
through an endosomal compartment that lacks clathrin but 
contains caveolin-1.
The results contrast another study that reported colocalization 
of PrP and clathrin in vesicles. But the cryoimmunogold EM 
method used by Peters et al. allows for higher resolution of the 
vesicles and their contents. Simian virus 40 particles were also 
shown to be taken in through caveolin-containing, clathrin-
negative structures that are connected to an endocytic vacuole 
(collectively termed caveosomes). Although the PrP-containing 
 
Stop and go L1CAM
 
mobile adhesion receptor allows 
a cell to migrate, whereas a 
stationary version of the same receptor 
keeps it in place, based on results 
from Gil et al. on page 
 
719
 
.
The immunoglobulin family member 
L1CAM promotes both growth cone 
extension in the developing central 
nervous system and cell adhesion-
mediated maintenance of axon bundles 
in mature neurons. How the same 
adhesion molecule regulates these 
disparate functions is not clear, 
particularly since the L1 family does 
not undergo the class switching (from 
adhesion-promoter to migration-
promoter) that seems to be common 
in integrins.
Rather than changing receptor 
types, L1CAM switches its own kinetic 
behavior to modulate cell movements. 
Stationary L1CAM, which may be 
associated with adhesion, was found 
to depend on ankyrin to stay in place. 
A 
 
vesicles lacked virus, the two atypical endocytic structures may be 
one and the same. If so, this EM study is the first ultrastructural 
view of caveosomes, which contain raft domains that are preferred 
by membrane-bound PrP.
Both the low pH and high concentration of raft lipids in the 
caveolin-containing compartment may favor PrP conversion to 
the pathogenic form. Therefore, the group expects that caveolin 
knock-out mice should be less susceptible to oral prions, but 
they await use of these mice to test their theory. In the mean-
time, they are testing whether drugs such as statins, which 
interfere with cholesterol-rich raft domains, might slow prion 
disease progression. 
 
 
 
Release of the ankyrin linkage, either 
with a peptide derived from the 
L1CAM cytoplasmic tail or via 
growth factors that phosphorylate 
the tail,increased the amount of 
L1CAM moving back along the upper 
surface of the cell. This retrograde 
movement depends on dynamic actin 
pools and is reminiscent of vesicles on 
treadmilling actin. The direction of 
L1CAM (green) interactions with 
ankyrin (red) prevent migration.
 
retrograde receptor movement seen 
on the upper surface of the cell is 
thought to reflect the direction of 
traction forces generated on the lower 
surface. In support of this theory, the 
authors found that peptide-mediated 
release of stationary L1CAM produced 
greater neurite extension through 
growth cone migration.
During development, neurons may 
switch from migration in the growth 
cone to adhesion in the axon and 
synapse by increasingly dephosphory-
lating L1CAM (and therefore 
promoting ankyrin binding). L1CAM–
ankyrin interactions may also be 
dynamically regulated in the growth 
cone to suppress traction forces that 
are incorrectly oriented. Peptides that 
interfere with L1CAM–ankyrin binding 
may one day be used therapeutically 
to awaken the retrograde movement 
of stationary L1CAM receptors in 
injured nerves. 
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